Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-201 for Gout Flare Prophylaxis During ULT Initiation
NCT01712204Phase 2Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Jan 2013
- Primary completion
- Sep 2013
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gout comparing AC-201 + Febuxostat with Placebo + Febuxostat (2 arms). Primary endpoint: Number of Gout Flares Per Subject at 16 weeks. Started Jan 2013; status: completed.
02
Drugs
AC-201CR
03
Conditions
gout
Beyond the preview
Go deeper on NCT01712204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712204.